Boston Scientific (BSX) 10-K Summaries & Annual Filing History
Review Boston Scientific Corporation (BSX) 10-K filings from 2023 through the latest annual report, including business, financial performance, risks, and liquidity.
Key takeaway
Year ended Dec 31, 2025 · FY2025 10-K
Boston Scientific Corporation filed its annual report for the latest fiscal year. The filing describes the company's medical device business, its financial results, and the risks it faces.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$20.1B
Revenue reported for the fiscal year.
Operating income
$3.6B
Income from operations reported for the year.
Net income
$2.9B
Net income reported for the year.
Operating cash flow
$4.5B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2022 | $12.7B | +6.7% |
| Dec 31, 2023 | $14.2B | +12.3% |
| Dec 31, 2024 | $16.7B | +17.6% |
| Dec 31, 2025 | $20.1B | +19.9% |
Business overview
The company develops, manufactures, and markets medical devices used in interventional cardiology, rhythm management, endoscopy, urology, and neurology. Its products address a range of conditions across the cardiovascular, respiratory, digestive, renal, and neurological systems. The business overview section outlines these core segments and the company's global operations.
Financial performance
Revenue increased during the period compared to the prior year, and both operating income and net income showed growth. Cash generated from operating activities also rose, reflecting improved financial performance.
Material risks
The filing identifies risks including potential adverse effects from healthcare regulation changes, product liability claims, and competition. It also cites risks related to supply chain disruptions, cybersecurity threats, and the need to innovate continuously in a highly regulated industry.
Liquidity and capital
The company discusses its liquidity and capital resources, noting that operating cash flow provides a primary source of funding for working capital, capital expenditures, and other obligations. The filing also references certain debt arrangements and share repurchase activities.
What to watch
Monitor the next filing for any updates on how the company is managing supply chain stability and regulatory compliance across its global markets.